As of 2026-09-16, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.01) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.49 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -101.1%.
The range of the Relative Valuation is (0.01) - (0.10) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.3x - 6.5x | 0.4x |
| Forward P/E multiples | 0.2x - 6.0x | 0.3x |
| Fair Price | (0.01) - (0.10) | (0.01) |
| Upside | -101.0% - -119.5% | -101.1% |
| Date | P/E |
| 2026-09-04 | -30.70 |
| 2026-09-03 | -30.70 |
| 2026-08-28 | -31.01 |
| 2026-08-24 | -31.32 |
| 2026-08-21 | -31.32 |
| 2026-08-20 | -31.32 |
| 2026-08-19 | -36.34 |
| 2026-08-14 | -35.71 |
| 2026-08-13 | -34.46 |
| 2026-08-12 | -34.46 |
| 2026-08-11 | -34.46 |
| 2026-08-10 | -33.83 |
| 2026-08-07 | -34.46 |
| 2026-08-06 | -35.08 |
| 2026-08-05 | -34.46 |
| 2026-08-04 | -33.20 |
| 2026-07-30 | -35.08 |
| 2026-07-24 | -34.46 |
| 2026-07-21 | -34.46 |
| 2026-07-17 | -34.46 |
| 2026-07-16 | -34.46 |
| 2026-07-13 | -34.46 |
| 2026-07-08 | -34.46 |
| 2026-07-07 | -33.20 |
| 2026-07-06 | -33.83 |
| 2026-07-03 | -33.83 |
| 2026-06-29 | -34.46 |
| 2026-06-26 | -34.46 |
| 2026-06-23 | -34.46 |
| 2026-06-19 | -34.46 |
| 2026-06-18 | -33.83 |
| 2026-06-15 | -34.46 |
| 2026-06-12 | -34.46 |
| 2026-06-11 | -34.46 |